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ABSTRACT 
Objective: The objective of the present study is a determination of the limiting solubility of dipyridamole in water and optimal ratios of 
polyethylene glycol:dipyridamole at which formation of solid dispersion is observed. 
Methods: UV-spectroscopy was used to determine the effect of polymer on limiting solubility of dipyridamole. Using low-temperature differential 
scanning calorimetry (DSC), it was made possible to obtain solid dispersions of dipyridamole with polyethylene glycols having average molecular 
weight 1000 and 1400. 
Results: The optimal ratio of polymer:Drug is 1:1, and is 3:1 for PEG-1000 and PEG-1400 respectively. Joint dissolution of dipyridamole with PEG-
1400 and PEG-1000 increases the drug content in the water by up to 8.1 times and up to 175 times, compared with the solution containing only 
dipyridamole. 
Conclusion: using systems based on dipyridamole and polyethylene glycol with average molecular weight of 1000, may increase the bioavailability 
of the drug and consequently reduce the dosages. Wide range of ratios, in which the formation of solid dispersions is possible, enables to adjust the 
solubility of dipyridamole in neutral aqueous media. 
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INTRODUCTION 
Dipyridamole is widely used for controlling and treating of angina 
pectoris, as well as to clinically prevent recurrence of myocardial 
infarction and thrombosis [1]. 
Dipyridamole is a drug with pH dependent solubility [2]. Since an 
increase of pH in gastro-intestinal tract reduces solubility of 
dipyridamole, the main places of its absorption are stomach and 
duodenum [3]. As the drug remains in the stomach for a short period 
of time than in the intestine, the bioavailability of dipyridamole upon 
oral administration would be low [4]. 
One of the main solutions to this problem is to create membrane-
controlled release pellets, gastric floating prolonged-release beads 
and none gastric resident sustained-release pellets [5-7]. On the 
other hand, increase in the aqueous solubility of dipyridamole by 
solubilizing polymers will improve the bioavailability of the drug in 
the intestine and would reduce the frequency of drug dose. 
Solubilizing agents used in the research work are biocompatible 
polymers – polyethylene glycols with average molecular weight of 
1000 (PEG-1000) and 1400 (PEG-1400). These polymers have 
proven themselves as a sample in the preparation of solid 
dispersions of hydrophobic drugs [8-10]. They are biocompatible 
[11], readily soluble in water [12] and less toxic [13]. It is important 
to note that highly hydrophilic character of polymer would increase 
the solubility of hydrophobic drugs associated with it. This improves 
the physical and chemical stability of formulations by preventing 
aggregation of drug in living organism and also during storage, due to 
the formation of so called “conformational cloud” [14]. 
Formation of dipyridamole solid dispersions based on polyethylene 
glycol with average molecular weight of 1000-1400 will significantly 
increase the solubility of the drug and reduce dipyridamole dosage. 
Wide range of ratios, in which the formation of solid dispersions is 
possible, will allow to regulate the solubility of poorly water-soluble 
drug – dipyridamole. 
Differential scanning calorimetry has shown the possibility of 
forming solid dispersions of dipyridamole with studied polyethylene 
glycols. Optimal ratio of polymer:Dipyridamole is 1:1 and 3:1 for 
PEG-1000 and PEG-1400 respectively. 
UV-spectrophotometry has shown that using of PEG-1000 as a 
solubilizing agent enables increase in the content of dipyridamole in 
water by 175 times. Such increase in solubility can be attained both 
by the solubilizing effect of polyethylene glycol and by decreasing 
the degree of crystallization of the drug due to the formation of solid 
dispersions. 
MATERIALS AND METHODS 
Materials 
Polyethylene glycol with molecular weight 950-1050 (PEG-1000), 
Aldriсh, Lot #MKBH0880V; polyethylene glycol with molecular 
weight 1305-1595 (PEG-1400), Aldriсh, Lot #BCBF0699V and 
dipyridamole 98%, Sigma, Lot # BCBK1596V were used without 
further purification. Deionized water was used as solvent. 
Preparation of mechanical mixtures 
Mechanical mixtures of polymers with dipyridamole were prepared 
by mixing measured quantities of substances in an agate mortar 
until complete homogenization. Mass ratios of polymer: 
dipyridamole were – 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 and 10:1. 
The resulting mixture is a yellow paste in case of PEG-1000, and 
yellow powder in case of PEG-1400. 
TG/DSC analysis 
The method of combined thermogravimetry and differential 
scanning calorimetry (TG/DSC) using thermal analyzer STA 449 C 
Jupiter (Netzsch, Germany) determines the thermal stability of 
dipyridamole, PEG-1000 and PEG-1400 in the temperature range of 
30-500 °C. The experiment was carried out in a dynamic atmosphere 
of argon (75 ml/min), at heating rate of 5 °C/min. Details of 
experiment are described earlier [15,16]. 
Presence of volatile impurities in mechanical mixtures of 
polymer:Dipyridamole and their thermal stability were studied at 
the temperature range of 30-200 °C. 
Low-temperature DSC analysis 
Enthalpies and transition temperature of dipyridamole, PEG-1000 
and PEG-1400, as well as their mechanical mixtures in the 
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temperature range of -60-200 °C were determined using differential 
scanning calorimeter DSC 204 F1 Phoenix (Netzsch, Germany), as 
described earlier [8,17]. Measurements were carried out on samples 
weighing 4-17 mg, at the heating rate of 5 °C/min (cooling 10 
°C/min), in a dynamic atmosphere of argon (150 ml/min). 
Study on aqueous solubility of dipyridamole 
Effect of polymer content on the limiting solubility of dipyridamole 
has been determined using the method of UV spectroscopy (UV-
spectrophotometer Lambda 35, Perkin-Elmer, USA). Different 
solutions were prepared with constant drug content of 20 mg/ml 
using various ratios of polymer:Dipyridamole (1:1, 2:1, 4:1, 6:1, 8:1 
and 10:1). After 24 hours, the solutions were separated from the 
undissolved part using a filter with pore diameter of 0.22 μl, and 
diluted 5 times for mixtures of PEG-1400:dipyridamole composition 
of 1-10:1 and PEG-1000:dipyridamole composition at 1:1, 10 times 
for mixture of PEG-1000:dipyridamole composition at 2:1, 20 times 
for the mixture of PEG-1000:dipyridamole mixture at 4:1, and 40 
times for mixtures of PEG-1000:dipyridamole composition 6-10:1. 
Solution containing only dipyridamole was not diluted. Increasing 
the content of the drug in water at 25 °C was determined as the ratio 
of absorbance values at a wavelength of 288 nm, which was obtained 
in the presence of various amounts of the polymer and without it. 
RESULTS AND DISCUSSION 
Results of TG/DSC analysis 
Figure 1 shows the results of combined TG/DSC analysis of 
dipyridamole. It is found that at temperature range of 30-200 °C, 
there is no significant loss in weight. At temperatures above 230 °C, 
thermal decomposition of dipyridamole begins and therefore, 
measurement of composites in low-temperature DSC analysis was 
carried out up to 200 °C in order to avoid decomposition. DSC curves 
of dipyridamole in the temperature range of 30-200 °C clearly show 
the endothermic effects corresponding to the polymorphic transition 
(peak temperature 130 °C) [18] and melting of the drug. Thermal 
effects on the DSC curve above 230 °C are associated with thermal 
degradation of dipyridamole. 
Loss of weight in the temperature range of 30-200 °C does not 
exceed 0.1%. For composites of dipyridamole with polyethylene 
glycols, weight loss in the temperature range of 30-200 °C does not 
exceed 1.2% in case of PEG-1000 and 0.3% in the case of PEG-1400, 
which means a complete absence of volatile impurities in the 
obtained mixtures. 
Data for PEG-1000 and PEG-1400 were obtained earlier [8,9]. 
 
 
Fig. 1: The results of TG/DSC analysis of dipyridamole in the 
dynamic atmosphere of argon at 75 ml/min, in the temperature 
range 30-500 °C. Heating rate is 5 °C/min. 
 
Results of low temperature DSC analysis of individual 
compounds 
For the more precise analysis of the thermal effects of phase 
transitions, including low-temperature region, method of low 
temperature differential scanning calorimetry was used. The results 
of DSC of dipyridamole in the temperature range of -60-200 °C are 
shown in Figures 2-7. The heating/cooling curves of dipyridamole 
(Figures 2-4) indicate an endothermic effect of melting which begins 
from 166.4 °C and 160.8 °C and enthalpy of 66.2 J/g and 54.2 J/g for 
the initial and second heating respectively. Onset of crystallization 
and enthalpy of corresponding exothermic peak is 140.9 °C and -
51.7 J/g respectively.  
DSC curve of initial heating also have endothermic effect with 
starting temperature of 91.5 °C and enthalpy of -21.6 J/g, which 
corresponds to the polymorphic transition of dipyridamole. Other 
effects on DSC curves were not observed in the studied temperature 
range. Onset temperature of melting/crystallization and corresponding 
enthalpy for polymers and dipyridamole is shown in Table 1. Data for 
PEG-1000 and PEG-1400 were taken from [8,9]. 
 
Table 1: Onset temperatures and enthalpy of phase transitions in initial samples of dipyridamole, PEG-1000 and PEG-1400. t1 – onset 
temperature of endothermic effect at initial heating, t2 – onset temperature of endothermic effect at second heating, t3 – onset 
temperature of exothermic effects while cooling, ΔH1 – enthalpy of endothermic effect at initial heating, ΔH2 – enthalpy of endothermic 
effect at second heating, ΔH3
Substance 
 – enthalpy at exothermic effects while cooling. Values for endothermic effect associated with polymorphic 
transition of dipyridamole are provided in brackets. 
t1 t, °С 2 t, °С 3 ∆H, °С 1 ∆H, J/g 2 ∆H, J/g 3, J/g 
Dipyridamole 166.4 (91.5) 160.8 140.9 66.2 (21.6) 54.2 -21.6 
PEG-1000 35.4 a 33.3 23.4 184.9 171.4 -167.5 
PEG-1400 45.6 b 42.5 33.1 194.0 174.2 -176.6 
a) Data from ref. [9], b)
 
 Data from ref. [8] 
Results of low-temperature DSC analysis of mixtures 
Thermo-physical properties of PEG-1000/dipiridamol and PEG-
1400/dipiridamol mixtures which are prepared in 1:1, 2:1, 3:1, 4:1, 
5:1, 6:1, 7:1, 8:1, 9:1 and 10:1, were studies using low-temperature 
DSC in the temperature range -60-200 °C. The results of analysis are 
shown in Figures 2-7.  
At initial heating of PEG-1000/dipiridamol mixtures (Figure 2), 
endothermic effects of polymer melting is fixed, while the 
endothermic effects of dipyridamole melting are not observed. This 
fact indicates the formation of solid dispersions of dipyridamole 
with PEG-1000 while blending. At second heating of the examined 
mixtures of PEG-1000:Dipyridamole (Figure 4), thermal effect of 
melting of the drug is also absent. Upon cooling of mixtures of PEG-
1000:Dipyridamole (Figure 3), exothermic effect in crystallization of 
the drug is not fixed, but composite shape of crystallization 
exothermic effects are observed for polyethylene glycol, which may 
be due to co-crystallization of dipyridamole with PEG-1000. 
In this connection, an optimal ratio of PEG-1000: Dipyridamole has a 
1:1, which does not have fixed separate crystalline phase of 
dipyridamole, and the drug content is maximum. 
During initial heating of mixtures PEG-1400/dipiridamol (Figure 5), 
endothermic effects of polymer melting are fixed. At ratio of 
polymer:drug 1-2:1 additionally contains less endothermic effects of 
dipyridamole melting.  
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Second heating of mixtures PEG-1400/dipiridamol (Figure 7) have a 
similar pattern, indicating that the formation of solid dispersions at 
a ratio of PEG-1400:dipyridamole more than 2:1 are observed. 
Crystallization exothermic effect of the drug is not fixed upon 
cooling of mixtures PEG-1400:dipyridamole (Figure 6). 
Thus, the optimal polymer:drug ratio is 1:1 and 3:1 for PEG-1000 
and PEG-1400 respectively. 
 
Fig. 2: DSC curves of PEG-1000, dipyridamole initial samples 
and their mixtures (1-10:1) in dynamic atmosphere of argon at 
150 ml/min, in the temperature range -60-200 °C (initial 
heating). Heating rate is 5 °C/min. 
 
 
Fig. 3: DSC curves of PEG-1000, dipyridamole initial samples 
and their mixtures (1-10:1) in dynamic atmosphere of argon at 
150 ml/min, in the temperature range -60-200 °C (cooling). 
Cooling rate is 10 °C/min. 
 
Fig. 4: DSC curves of PEG-1000, dipyridamole initial samples 
and their mixtures (1-10:1) in dynamic atmosphere of argon at 
150 ml/min, in the temperature range -60-200 °C (second 
heating). Heating rate is 5 °C/min. 
 
Effect of polymer on solubility of dipyridamole in water 
Using UV-spectrophotometry technique, it was proved that the 
presence of polymer increases the concentration of dipyridamole in 
the water solution. At Figure 8 has plotted values of increase in 
dipyridamole content in aqueous solution where there is varying 
amounts of polyethylene glycols. 
 
Fig. 5: DSC curves of PEG-1400, dipyridamole initial samples 
and their mixtures (1-10:1) in dynamic atmosphere of argon at 
150 ml/min, in the temperature range -60-200 °C (initial 
heating). Heating rate is 5 °C/min. 
 
Fig. 6: DSC curves of PEG-1400, dipyridamole initial samples 
and their mixtures (1-10:1) in dynamic atmosphere of argon at 
150 ml/min, in the temperature range -60-200 °C (cooling). 
Cooling rate is 10 °C/min. 
 
Fig. 7: DSC curves of PEG-1400, dipyridamole initial samples 
and their mixtures (1-10:1) in dynamic atmosphere of argon at 
150 ml/min, in the temperature range -60-200 °C (second 
heating). Heating rate is 5 °C/min. 
 
 
Fig. 8: Increase in dipyridamole content in aqueous solution in 
the presence of PEG-1000 and PEG-1400 according to UV 
spectrophotometric analysis. Ratio of polymer:dipyridamole 
1:1, 2:1, 4:1, 6:1, 8:1 and 10:1. Optical density is taken at a 
wavelength of 288 nm. 
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Figure 8 shows that even at a ratio of PEG-1000:Dipyridamole of 1:1, 
dipyridamole concentration in the solution is 15 times higher than in 
the aqueous solution of the drug. When the ratio of PEG-1000: 
Dipyridamole is equal to 10:1, dipyridamole content in aqueous 
solution increases in 175 times. Inclusion of polymer in the PEG-
1400 solution also increases the solubility of dipyridamole, but to a 
lesser extent. Thus, when the ratio of PEG-1400:Dipyridamole is 
equal to 10:1, the increase in solubility is not more than 8.1 times 
(Figure 8). 
Thus, by using polyethylene glycol with an average molecular weight 
of 1000, solubility of hydrophobic drug – dipyridamole is up to 175 
times, which in turn enhance the absorbability of the drug and 
neutral solutions and as a result, increases its effectiveness. 
CONCLUSIONS 
At the present work examined the thermal properties of composites 
based on polyethylene glycol and hydrophobic drug – dipyridamole. 
Low temperature differential scanning calorimetry showed that 
polyethylene glycols with an average molecular weight of 1000 and 
1400 are capable of forming solid dispersion with dipyridamole. The 
optimal ratio of polymer:Drug is 1:1, and is 3:1 for PEG-1000 and 
PEG-1400 respectively. 
UV-spectrophotometry method indicated that joint dissolution of 
dipyridamole with PEG-1400 and PEG-1000 increases the drug 
content in the water by up to 8.1 times and up to 175 times, 
compared with the solution containing only dipyridamole. 
Using systems based on dipyridamole and polyethylene glycol with 
average molecular weight of 1000, may increase the bioavailability 
of the drug and consequently reduce the dosages. Wide range of 
ratios, in which the formation of solid dispersions is possible, 
enables to adjust the solubility of dipyridamole in neutral aqueous 
media. 
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